{"name":"Saol Therapeutics Inc","slug":"saol-therapeutics-inc","ticker":"","exchange":"","domain":"saol.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SL1002","genericName":"SL1002","slug":"sl1002","indication":"Chronic hepatitis C virus infection","status":"phase_3"}]}],"pipeline":[{"name":"SL1002","genericName":"SL1002","slug":"sl1002","phase":"phase_3","mechanism":"SL1002 is a recombinant human serum albumin-interferon alpha fusion protein that enhances innate immune responses against viral infections and cancer.","indications":["Chronic hepatitis C virus infection","Melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPNVRSMUtERVNLT3BpVk9iVkJnS1ZNdFc5QmZIOXVtcTdFcFVtaWtqRnB5WVNpRGp1WE8yNkYwYUMyZFlnaXAyaG5abXlPZS0tZXdIWlZvTmZ0ci1od0VHZkM1cE41bXRmaWFjVzFwcTVZbFdISWMwZ0gxc0hYZW9KZnJBLV9aYXQzdXV3S2E2c0pmOElDRnNzRlJiOHlxMURoYUdjR0tnNUFzNUdZSTNOUGpDRFJwU0lFY2RHTnpuQWlfUDhiVm04RXVDVlFFUV9IczM2cEtlWDJWbVZTQlR2dDkzOURkZ29IWUZuUFJHbll2TXhuYU42ZFRpSVloVG9QVE0tSl93Z21sdVNRLXNTcURZdUNmUGc2czRIcTZETTUxbllPTTNjV1FuNG5MWWQzVTA3V3Q2SVFLZTE5TGRFeFpwQ0l1eTlQbUxsbl9uYw?oc=5","date":"2026-03-25","type":"trial","source":"Barchart.com","summary":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stages, Finds DelveInsight | Biosplice Therapeutics, Regeneron Pharmaceuticals - Barc","headline":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxQSXNOQnE3NE1RcWtsbkd1S2RTWGxsN0dtTVktTE1xaFkwZHZFcmlVT1VjV0RseGZvSmVIZURxQ0NKc1p1Q1pQNGtIdEVBNDhqOC0wckZmajdHWGE2T1lYZUtEWkRWcll0Yjh3ci04TmJDVlY0MW10RWFuYk1HY0Jxck5YcE43VktlUUNHanJUc1pScDdrSU9Md2k0bDVBb21kZm9VN2dWenl0N0hMbG56X183R2Jjam44MWRlaE10NkxlM2FPUWJkTWlyOFlCWlVtNVZDTzVDQkpLalJIZ3pHV3lOMGtPSjZQeEVTSGI3S0NxeUhBRktQdkRLaUlTck1TdWFMeFNIZzV5ZWpaLW5WSjNJY1BEYUtPZF9ybWxHYWxPd0l0NlZQUXpYUDVPX3QyWEtpQXhR?oc=5","date":"2025-12-09","type":"regulatory","source":"PR Newswire","summary":"Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency (PDCD) - PR Newswire","headline":"Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate De","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQb3lIeTgyNXJ2ZFVJRTFpeE1jTjM1SHRIcDNQQUZtSUtRWFJXaUd2WGNWTHZpSkd1SXVtUXJydkVQRkt2UlhnM1JFUU15dWVrdzUzeVBRR1FRN3BXdlh4QnRGanBiTE9mcVZheTBJaFNiR3FENFVwVGZ4X2pwUHJrRl9qcU01cW1TNFlOVzRSbzJmQmxiOHBEX05vOF9CR1ZrQUlfQ3VDekxVbjRZd1JN?oc=5","date":"2025-10-31","type":"regulatory","source":"MedCity News","summary":"Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease - MedCity News","headline":"Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQM21KLTFNRXlyOThlMThJeDd6ay1acE1PMVRkUDFfRm5wWWQwSHRMVW9nQmV2WFJabi1XRXdPaUQzU3JpOS1sUVAwd1hvVnh6NUU4ekFZOWRwQWFTLXljOFFJOGx6MW94Q2QtOTFIcEhRUkVLTmR4TDBiTEpOWmlEVEVqeTZjWkhrS012MzBTcnlJVFZBdEE0dEh0RzI?oc=5","date":"2025-09-09","type":"pipeline","source":"BioWorld News","summary":"Saol Therapeutics hit with CRL for rare genetic disease - BioWorld News","headline":"Saol Therapeutics hit with CRL for rare genetic disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOZVhnWmVHcXRYbDZOckpfajZnZHk1cWhDVFlPdmlDOUNyY3I0X0ptSG1iazNEdFc3N0lfYTBmVHVBazIwazAzOXlkaVRDdWdkaWpvQmVqVmtHSnN3dVk4TzRhX2tqMjNJc05mSkRNY3ctNmMyMFVtNmpwVDVLV21VMHhyVm5LZlVISThzWkxXNjVIWW4xT1hPX0Q4VXBtc0l3WkxHREtibkFTUDh6ek9ITGhTRnVlZXFVTTh1dzZHRTBnWU9pSHBjX0lieEVxRFlpLVdxTEFPRndaSU9JODZpeS1lY0RkTU9VUl9oUXFneG41MmRESnZ3UkF4Q25EOE1lb1FaWXVxbXlUOGhNaFNSNVVDRXhQcUhDWUczQ1hXVTZHb2g4akE?oc=5","date":"2025-09-08","type":"regulatory","source":"PR Newswire","summary":"Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD) - PR Newswire","headline":"Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNT2pyU2NScEJJWkh5dER3X0FBOGoyMWZuYURSUC1pNWtqX2FiRjF0bkp0NzdFa18yMEdnc3VQLUx3ZmpMYWxhQjd2MWtDLXZIWGRYOHVicUd2YlNjSGRKLURXZkZzSjBGaFE4cE9SS0pKNzJGaWFXamk3d2VxS05ld0hYaHM1b3czVVFjYy1PamRHQnFSTVZSY2lQTnhjYmFvMDhXdW5rQ1YzTUlBQk4wYnI2TS1EN0NfTFU4SW16VTVzakVEN2Y2elhaek1zUEduS1J1cEFqT3o2R3dTcThJ?oc=5","date":"2025-04-17","type":"pipeline","source":"PR Newswire","summary":"Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs - PR Newswire","headline":"Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxNSWFUT0QzRWhEend6SHBzY21KX2VXYVJQUTNIbnR3QzJKRGp1TWNYYU53UGFFbFlvUUgyMUt5OEVucHNiZWRIQTBIenN5V2piTzBTaTBSY29ObDBLN0hwcnM2ZWJCdGVuQVl3VVk1SmVEMmFsNXJISEc3UjBUdGhxRGhqU3ZRNGo5YWQ0Z3otOXZBbmZ3dG55ejJUSXN5czRsMG8za0FCOEs5bDQwZDBWSWFkQkFOVEt0ZUNIeUhqOFdqRmJzUkR2aUx0WFpGSlNWa3pwbHdndDJHalgzWjhoRU56ODNpdnBVb0xzVlRFNDRCMm84aHM2d082cmV3d25XSG9ZTFhRM09UZTZ0UGlEVGYwZ1dTQ1c2UVVnMQ?oc=5","date":"2025-01-28","type":"regulatory","source":"PR Newswire","summary":"Saol Therapeutics announces FDA acceptance of New Drug Application for SL1009 for treatment of Pyruvate Dehydrogenase Complex Deficiency - PR Newswire","headline":"Saol Therapeutics announces FDA acceptance of New Drug Application for SL1009 for treatment of Pyruvate Dehydrogenase Co","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxOT0F1T2ZrdlpaS2tlbHVBbi1sMXRwRFF2MlRjS1I4SlNfeDR6cVdZZTBpNzRnVHFucUl6anlvRzNiWEVwOHNZaU9Ga3R5Uk4tVXE4MkFBbGRaNTg3RERzWnUyVWowUlBpV2FkMnZTeGkxQWxLeUhxMElfNE9vTkZlRUtQeGtUeVhwaXBvT0xqc1hjQnViUFNfY2ZPVXhRbTFfNHVyaVR4c3g2empDQ1pmdHVZX0c2Yl9ab1NyTzYyZEtwd0VMQjZfeXZyaHlmTWFpTl92bFd6T2lnekxYd0xqRVFrWUYtV2xfeERDbF81QmxyS2FtMU1mRC1BQ2kwSV9VekZYOXdUMzNZYTJIZEN6RndfZnZOSzJVeklmazRwbDF0aU9mTXg0LUlySXYtRGdVQW1Bbkp3ZTM?oc=5","date":"2023-09-19","type":"trial","source":"PR Newswire","summary":"Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial - PR Newswire","headline":"Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}